Pharma — December 2021
-
Alnylam Submits Applications In U.S, EU To Support Label Expansion For Oxlumo For PH1 Treatment https://www.proinvestor.com/investornyt/749126/alnylam-submits-applications-in-us-eu-to-support-label-expansion-for-oxlumo-for-ph1-treatment
-
Bristol Myers Squibb a Top 25 Dividend Giant With 3.66% Yield (BMY) https://www.proinvestor.com/investornyt/749108/bristol-myers-squibb-a-top-25-dividend-giant-with-366-yield-bmy
-
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
https://www.proinvestor.com/investornyt/749116/2-healthcare-stocks-you-can-buy-and-hold-for-the-next-decade -
FDA Approves AbbVie's RINVOQ To Treat Active Psoriatic Arthritis https://www.proinvestor.com/investornyt/749504/fda-approves-abbvies-rinvoq-to-treat-active-psoriatic-arthritis
-
Merck KgaA Signs Deal With IB To Support Establishment Of Vaccine Production Facility In Nigeria https://www.proinvestor.com/investornyt/749514/merck-kgaa-signs-deal-with-ib-to-support-establishment-of-vaccine-production-facility-in-nigeria
-
AstraZeneca Exercises License Option For Oncolytic Virus Generated From Invir.IO Collaboration https://www.proinvestor.com/investornyt/749536/astrazeneca-exercises-license-option-for-oncolytic-virus-generated-from-invirio-collaboration
-
Sanofi & GSK Report Positive Preliminary Booster Data For COVID-19 Vaccine Candidate https://www.proinvestor.com/investornyt/749546/sanofi-amp-gsk-report-positive-preliminary-booster-data-for-covid-19-vaccine-candidate
-
Eli Lilly Investor Conference Call At 9:00 AM ET
https://www.proinvestor.com/investornyt/749579/eli-lilly-investor-conference-call-at-900-am-et -
Eli Lilly opjusterer omsætnings- og indtjeningsprognosen https://www.proinvestor.com/investornyt/749626/eli-lilly-opjusterer-omsaetnings-og-indtjeningsprognosen
-
J
ohnson & Johnson Receives Positive CHMP Opinion For Booster Shot Of COVID-19 Vaccine https://www.proinvestor.com/investornyt/749726/johnson-amp-johnson-receives-positive-chmp-opinion-for-booster-shot-of-covid-19-vaccine -
Novartis Plans New $15 Bln Share Buyback To Be Executed By 2023-end
https://www.proinvestor.com/investornyt/750174/novartis-plans-new-15-bln-share-buyback-to-be-executed-by-2023-end -
Innate : First Patient Dosed In IPH6101/SAR443579 Phase 1/2 Trial In Various Blood Cancers https://www.proinvestor.com/investornyt/750170/innate-first-patient-dosed-in-iph6101-sar443579-phase-1-2-trial-in-various-blood-cancers
-
God morgen.
-
Biogen's Alzheimer's Drug To Enter New Trial Stage Next Year https://www.proinvestor.com/investornyt/750868/biogens-alzheimers-drug-to-enter-new-trial-stage-next-year
-
Roche Gets CE Mark For Use Of Saliva Samples With Cobas SARS-CoV-2 Qualitative Test https://www.proinvestor.com/investornyt/750884/roche-gets-ce-mark-for-use-of-saliva-samples-with-cobas-sars-cov-2-qualitative-test
-
ObsEva: Linzagolix Gets Positive CHMP Opinion For Uterine Fibroids - Quick Facts https://www.proinvestor.com/investornyt/750888/obseva-linzagolix-gets-positive-chmp-opinion-for-uterine-fibroids-quick-facts
-
Ipsen, GENFIT Enter Long-term Collaboration; Ipsen Becomes Shareholder Of GENFIT https://www.proinvestor.com/investornyt/750889/ipsen-genfit-enter-long-term-collaboration-ipsen-becomes-shareholder-of-genfit
-
Basilea Pharma: FDA Allows To Proceed With Phase 1 Study For BAL0891 https://www.proinvestor.com/investornyt/750892/basilea-pharma-fda-allows-to-proceed-with-phase-1-study-for-bal0891
-
CDC Recommends Pfizer, Moderna COVID-19 Vaccines Over J&J Due To Rare Blood Clots https://www.proinvestor.com/investornyt/750860/cdc-recommends-pfizer-moderna-covid-19-vaccines-over-jampj-due-to-rare-blood-clots
-
Merck: CHMP Adopts Positive Opinion For KEYTRUDA As Monotherapy For Adjuvant Treatment Of RCC https://www.proinvestor.com/investornyt/750960/merck-chmp-adopts-positive-opinion-for-keytruda-as-monotherapy-for-adjuvant-treatment-of-rcc
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind